363 related articles for article (PubMed ID: 17314076)
1. Gastric cancer after positive screening faecal occult blood testing and negative assessment.
Zappa M; Visioli CB; Ciatto S; Grazzini G; Rubeca T; Bonanomi AG; Confortini M; Paci E; Castiglione G
Dig Liver Dis; 2007 Apr; 39(4):321-6. PubMed ID: 17314076
[TBL] [Abstract][Full Text] [Related]
2. Limitations of the faecal occult blood test in screening for colorectal cancer.
Delcò F; Sonnenberg A
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
[TBL] [Abstract][Full Text] [Related]
3. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic findings in the upper gastrointestinal tract of faecal occult blood-positive, colonoscopy-negative patients.
Hisamuddin K; Mowat NA; Phull PS
Dig Liver Dis; 2006 Jul; 38(7):503-7. PubMed ID: 16522381
[TBL] [Abstract][Full Text] [Related]
5. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
[TBL] [Abstract][Full Text] [Related]
6. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
7. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M;
J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
Tsoi KK; Ng SS; Leung MC; Sung JJ
Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
[TBL] [Abstract][Full Text] [Related]
9. The positive predictive value of guaiac faecal occult blood test in relation to the number of positive squares in two consecutive rounds of colorectal cancer screening.
Manfredi S; Philip J; Campillo B; Piette C; Durand G; Riou F; Bretagne JF
Eur J Cancer Prev; 2011 Jul; 20(4):277-82. PubMed ID: 21633201
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
[TBL] [Abstract][Full Text] [Related]
11. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
[TBL] [Abstract][Full Text] [Related]
12. Familial risk of colorectal cancer in subjects attending an organised screening programme.
Castiglione G; Visioli CB; Zappa M; Grazzini G; Mallardi B; Mantellini P
Dig Liver Dis; 2012 Jan; 44(1):80-3. PubMed ID: 21925983
[TBL] [Abstract][Full Text] [Related]
13. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of immunological fecal occult blood testing for colorectal cancer screening.
Nakama H; Kamijo N
Prev Med; 1994 May; 23(3):309-13. PubMed ID: 8078851
[TBL] [Abstract][Full Text] [Related]
15. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
[TBL] [Abstract][Full Text] [Related]
16. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood.
Trojan J; Povse N; Schröder O; Stein J
Z Gastroenterol; 2002 Nov; 40(11):921-4. PubMed ID: 12436369
[TBL] [Abstract][Full Text] [Related]
17. Socio-geographical determinants of colonoscopy uptake after faecal occult blood test.
Dupont-Lucas C; Dejardin O; Dancourt V; Launay L; Launoy G; Guittet L
Dig Liver Dis; 2011 Sep; 43(9):714-20. PubMed ID: 21530429
[TBL] [Abstract][Full Text] [Related]
18. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
Malila N; Oivanen T; Hakama M
Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
[TBL] [Abstract][Full Text] [Related]
19. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
Clarke P; Jack F; Carey FA; Steele RJ
Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
[TBL] [Abstract][Full Text] [Related]
20. A 25-year follow-up of a population screened with faecal occult blood test in Finland.
Malila N; Hakama M; Pukkala E
Acta Oncol; 2007; 46(8):1103-6. PubMed ID: 17851857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
